Compare WEAV & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEAV | DNA |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | 485 |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 487.7M | 455.8M |
| IPO Year | 2021 | N/A |
| Metric | WEAV | DNA |
|---|---|---|
| Price | $5.52 | $7.79 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 2 |
| Target Price | ★ $11.00 | $8.50 |
| AVG Volume (30 Days) | 911.3K | ★ 1.2M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $239,024,000.00 | N/A |
| Revenue This Year | $17.20 | N/A |
| Revenue Next Year | $13.74 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.99 | N/A |
| 52 Week Low | $4.24 | $5.37 |
| 52 Week High | $9.10 | $17.58 |
| Indicator | WEAV | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 47.38 | 43.08 |
| Support Level | $4.93 | $7.59 |
| Resistance Level | $5.56 | $9.58 |
| Average True Range (ATR) | 0.29 | 0.76 |
| MACD | -0.06 | -0.14 |
| Stochastic Oscillator | 22.31 | 5.86 |
Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses, that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more, enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and revenue from subscription services.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.